“…It is confirmed that ISCOMs are highly effective adjuvant systems capable of inducing a broad range of immune responses, including balanced Th1 and Th2 CD4(+) T‐cell priming, cytotoxic T lymphocyte cell responses, specific serum antibodies and a strong mucosal immunoglobin A (IgA) response (Anja et al, ; Morein, Hu, & Abusugra, ). In addition, many studies showed that ISCOMs enhanced innate immune responses in mammals, such as inducing the expression of interleukin (IL)‐1B, chemokine ligand 8 (CXCL8), IL‐12B, IL‐17A, interferon (IFN)‐α and Toll‐like receptor 2 (TLR2) (Ahlberg et al, ; Ahlberg, Lovgren Bengtsson, Wallgren, & Fossum, ; Fossum et al, ). Hence, ISCOMs have a broad spectrum of immune responses and can be administered through the mucosal membrane.…”